Benign Prostatic Hyperplasia Procedures in Patients with Prostate Cancer:: What Do We Know?
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: PCa, including those managing with active surveillance or pursuing radiation treatment
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Ultimately, treatment selection requires shared decision-making and a multidisciplinary approach to achieving symptom relief while maintaining cancer control. Future research will be critical to refine best practices and assess long-term outcomes in these clinical situations.
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) frequently coexist, posing unique challenges for the clinician.
APA
Scovell JM, Kelebeyev S, et al. (2025). Benign Prostatic Hyperplasia Procedures in Patients with Prostate Cancer:: What Do We Know?. The Urologic clinics of North America, 52(4), 617-628. https://doi.org/10.1016/j.ucl.2025.07.003
MLA
Scovell JM, et al.. "Benign Prostatic Hyperplasia Procedures in Patients with Prostate Cancer:: What Do We Know?." The Urologic clinics of North America, vol. 52, no. 4, 2025, pp. 617-628.
PMID
41106990 ↗
Abstract 한글 요약
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) frequently coexist, posing unique challenges for the clinician. This article explores how various surgical and minimally invasive therapies for BPH can be utilized in patients with PCa, including those managing with active surveillance or pursuing radiation treatment. The discussion herein highlights the efficacy, complications, and oncological implications of these treatments. Ultimately, treatment selection requires shared decision-making and a multidisciplinary approach to achieving symptom relief while maintaining cancer control. Future research will be critical to refine best practices and assess long-term outcomes in these clinical situations.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.